Recursion Pharmaceuticals Stock News

SALT LAKE CITY , Dec. 20, 2022 /PRNewswire/ --  Recursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced its participatio

Recursion Pharmaceuticals is using artificial intelligence to make the drug discovery process efficient. They have a diverse pipeline.

Recursion Pharmaceuticals (RXRX) delivered earnings and revenue surprises of 2.78% and 104.57%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the

Here's why three Fool.com contributors love Vertex Pharmaceuticals, Repligen, and Recursion Pharmaceuticals.

SALT LAKE CITY , Sept. 1, 2022 /PRNewswire/ -- Recursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced its participation

Here's why we like SeaSpine, Recursion Pharmaceuticals, and Agenus.

Here's why our roundtable likes 10x Genomics, Beam Therapeutics, and Recursion Pharmaceuticals.

Recursion Pharmaceuticals (RXRX) delivered earnings and revenue surprises of -164.71% and 96.51%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the s

SALT LAKE CITY , May 2, 2022 /PRNewswire/ -- Recursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced its participation in

In the last trading session, 2.56 million shares of the Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) were traded. Most recently the company’s share price was $7.09, and it changed around -$0.56 or -7.32% from the last close, which brings the market valuation of the company to $1.52B. RXRX currently trades at a discount to its 52-week high … Why Recursion Pharmaceuticals Inc. (NASDAQ: RXRX) Stock Should Not Be Taken For Granted By Investors In 2022 Read More »

The shares of the clinical-stage biotechnology company Recursion Pharmaceuticals <> are set to close at an all-time low on Thursday after the company announced a delay for its Phase…

SALT LAKE CITY, March 2, 2022 /PRNewswire/ -- Recursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced its participation

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX)s traded shares stood at 0.65 million during the last session. At the close of trading, the stocks price was $11.99, to imply an increase of 1.70% or $0.2 in intraday trading. The RXRX shares 52-week high remains $42.81, putting it -257.05% down since that peak but still an impressive 17.76% since Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) Plunging -46.64% In 6 Months Heres What To Expect Read More »

SALT LAKE CITY, Feb. 8, 2022 /PRNewswire/ --  Recursion  (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced its participatio

Recursion Pharma is hoping to revolutionize drug discovery with its Recursion OS technology; potential to improve drug discovery and processing capabilities. Recent deal with Roche brought in an upfro